Literature DB >> 10485463

Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis.

U R Peters1, M P Tschan, K A Kreuzer, G Baskaynak, U Lass, A Tobler, M F Fey, C A Schmidt.   

Abstract

The role of the recently identified first p53-homologue, p73, in neoplastic transformation is unknown. To elucidate p73 gene expression in hematopoiesis, we investigated samples from chronic myeloid leukemia (CML) and acute myeloid leukemia patients, leukemia cell lines, as well as mature and immature normal hematopoietic cells by real-time quantitative RT-PCR and Western blot analysis. We found a distinct p73 expression profile with highest p73 mRNA transcript levels in hematopoietic malignancies such as CML blast crisis and acute myelogenous leukemia versus CML chronic phase and normal controls. Mono- and biallelic p73 expression was found in both normal and malignant hematopoiesis. p73 protein was expressed at various levels in leukemia samples and cell lines but could not be detected in any normal controls tested. Our results point to a distinct yet undefined role of p73 in the pathogenesis of myeloid neoplasms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485463

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  p73alpha is a candidate effector in the p53 independent apoptosis pathway of cisplatin damaged primary murine colonocytes.

Authors:  A Oniscu; N Sphyris; R G Morris; S Bader; D J Harrison
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

2.  Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness.

Authors:  Chantal Lagresle-Peyrou; Emmanuelle M Six; Capucine Picard; Frédéric Rieux-Laucat; Vincent Michel; Andrea Ditadi; Corinne Demerens-de Chappedelaine; Estelle Morillon; Françoise Valensi; Karen L Simon-Stoos; James C Mullikin; Lenora M Noroski; Céline Besse; Nicolas M Wulffraat; Alina Ferster; Manuel M Abecasis; Fabien Calvo; Christine Petit; Fabio Candotti; Laurent Abel; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Nat Genet       Date:  2008-11-30       Impact factor: 38.330

3.  p73 plays a role in erythroid differentiation through GATA1 induction.

Authors:  Fernando Marqués-García; Nuria Ferrandiz; Rosalía Fernández-Alonso; Laura González-Cano; Marta Herreros-Villanueva; Manuel Rosa-Garrido; Belén Fernández-García; José P Vaque; Margarita M Marqués; María Eugenia Alonso; José Carlos Segovia; Javier León; María C Marín
Journal:  J Biol Chem       Date:  2009-06-09       Impact factor: 5.157

4.  Detection of p73 antibodies in patients with various types of cancer: immunological characterization.

Authors:  O Tominaga; K Unsal; G Zalcman; T Soussi
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

5.  ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype.

Authors:  Antonio R Lucena-Araujo; Juan L Coelho-Silva; Diego A Pereira-Martins; Carolina Thomé; Priscila S Scheucher; Ana P Lange; Helder H Paiva; Benjamin T Hemmelgarn; Mariana C Morais-Sobral; Elisa A Azevedo; Pedro L Franca-Neto; Rafael F Franca; Cleide L Silva; Alexandre Krause; Eduardo M Rego
Journal:  Oncotarget       Date:  2017-01-31

6.  High-resolution analysis of aberrant regions in autosomal chromosomes in human leukemia THP-1 cell line.

Authors:  Naoki Adati; Ming-Chih Huang; Takahiro Suzuki; Harukazu Suzuki; Toshio Kojima
Journal:  BMC Res Notes       Date:  2009-07-27

7.  p73 expression is associated with cellular chemosensitivity in human non-small cell lung cancer cell lines.

Authors:  Kaishan Liu; Xiaomei Zhuang; Zhuoying Mai
Journal:  Oncol Lett       Date:  2012-11-19       Impact factor: 2.967

8.  Overexpressed TP73 induces apoptosis in medulloblastoma.

Authors:  Robert C Castellino; Massimiliano De Bortoli; Linda L Lin; Darlene G Skapura; Jessen A Rajan; Adekunle M Adesina; Laszlo Perlaky; Meredith S Irwin; John Y H Kim
Journal:  BMC Cancer       Date:  2007-07-12       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.